Prognostic indicators of survival in ALS
Abstract
We analyzed data from the 245-patient placebo group of the ALS CNTF Treatment Study Group study, a large, prospective, multicenter study of recombinant human ciliary neurotrophic factor to determine prognostic factors for length of survival in ALS. Variables examined included baseline demographic characteristics, indices of disease severity, pulmonary function, and clinical laboratory tests. Shorter survival was associated with greater age, lower percent-predicted forced vital capacity (FVC%), and lower serum chloride at study entry. A shorter interval from symptom onset to diagnosis of ALS and greater weight loss in the 2 months before study entry also predicted shortened survival times. The rate of muscle strength loss before study entry did not predict risk of mortality. Serum chloride, reflecting the degree of respiratory acidosis, was identified for the first time as being correlated with prognosis in ALS. The relationship between a patient's FVC% and the probability of survival is described.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
2.
Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-1322.
3.
Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985;232:295-300.
4.
Kondo K, Hemmi I. Clinical statistics in 515 fatal cases of motor neuron disease. Neuroepidemiology 1984;3:129-148.
5.
Preux P-M, Couratier PH, Boutros-Toni F, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 1996;15:153-160.
6.
Cedarbaum JM, Stambler N. Performance of the ALS Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997;152(Suppl 1):1-9.
7.
Bensimon G, Lacomblez L, Meininger, the ALS Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
8.
Fallat RJ, Jewitt B, Bass M, et al. Spirometry in amyotrophic lateral sclerosis. Arch Neurol 1979;36:74-80.
9.
ALS CNTF Treatment Study (A.C.T.S.) Group. A double-blind, placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis(ALS). Neurology 1996;46:1244-1249.
10.
Andres PL, Hedlund W, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
11.
Brooks BR. Amyotrophic lateral sclerosis clinimetric scales-guidelines for administration and scoring. In: Herndon R, ed. Handbook of clinical neurologic scales. New York: Demos Vermande, 1997:27-79.
12.
Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979;119:895-902.
13.
Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193-1198.
14.
Gold WM. Pulmonary function testing. In: Murray JF, Nadel JA, eds. Respiratory medicine, 2nd ed. Philadelphia: WB Saunders, 1994:871.
Information & Authors
Information
Published In
Copyright
© 1998.
Publication History
Published online: January 1, 1998
Published in print: January 1998
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Gut microbiota immune cross-talk in amyotrophic lateral sclerosis, Neurotherapeutics, 21, 6, (e00469), (2024).https://doi.org/10.1016/j.neurot.2024.e00469
- Serum chloride as a respiratory failure marker in amyotrophic lateral sclerosis, Frontiers in Aging Neuroscience, 15, (2023).https://doi.org/10.3389/fnagi.2023.1188827
- Management of motor neuron disease with updated therapies: A review, IP Indian Journal of Neurosciences, 9, 1, (1-7), (2023).https://doi.org/10.18231/j.ijn.2023.001
- How to increase noninvasive ventilation effectiveness in bulbar amyotrophic lateral sclerosis patients, Breathe, 19, 1, (220266), (2023).https://doi.org/10.1183/20734735.0266-2022
- Evaluation of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis, European Journal of Neurology, 30, 6, (1611-1618), (2023).https://doi.org/10.1111/ene.15779
- Predicting amyotrophic lateral sclerosis (ALS) progression with machine learning, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25, 3-4, (242-255), (2023).https://doi.org/10.1080/21678421.2023.2285443
- Modulators of ASIC1a and its potential as a therapeutic target for age-related diseases, Ageing Research Reviews, 83, (101785), (2023).https://doi.org/10.1016/j.arr.2022.101785
- Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686], PLOS ONE, 17, 6, (e0258614), (2022).https://doi.org/10.1371/journal.pone.0258614
- Theme 12 - Clinical Management and Support, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23, sup1, (176-194), (2022).https://doi.org/10.1080/21678421.2022.2120688
- China amyotrophic lateral sclerosis registry of patients with Traditional Chinese Medicine (CARE-TCM): Rationale and design, Journal of Ethnopharmacology, 284, (114774), (2022).https://doi.org/10.1016/j.jep.2021.114774
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.